Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Sees Significant Growth in Short Interest

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totaling 375,939 shares, an increase of 67.5% from the September 30th total of 224,403 shares. Based on an average daily volume of 168,469 shares, the days-to-cover ratio is currently 2.2 days. Currently, 3.0% of the company’s stock are sold short.

Analyst Ratings Changes

Several equities research analysts have issued reports on TVRD shares. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. BTIG Research reduced their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a research report on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, October 2nd. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.40.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $63,000. BlackRock Inc. bought a new position in Tvardi Therapeutics during the second quarter worth $181,000. Finally, GSA Capital Partners LLP bought a new position in Tvardi Therapeutics during the second quarter worth $34,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Up 3.7%

Shares of TVRD stock opened at $0.83 on Wednesday. Tvardi Therapeutics has a one year low of $0.77 and a one year high of $5.69. The company’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $2.73.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts predict that Tvardi Therapeutics will post -2.23 earnings per share for the current year.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.